Retinal imaging in Alzheimer's and neurodegenerative diseases

Peter J. Snyder, Jessica Alber, Clemens Alt, Lisa J. Bain, Brett E. Bouma, Femke H. Bouwman, Delia Cabrera DeBuc, Melanie C. W. Campbell, Maria C. Carrillo, Emily Y. Chew, M. Francesca Cordeiro, Michael R. Dueñas, Brian M. Fernández, Maya Koronyo-Hamaoui, Chiara la Morgia, Roxana O. Carare, Srinivas R. Sadda, Peter van Wijngaarden, Heather M. Snyder*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

In the last 20 years, research focused on developing retinal imaging as a source of potential biomarkers for Alzheimer's disease and other neurodegenerative diseases, has increased significantly. The Alzheimer's Association and the Alzheimer's & Dementia: Diagnosis, Assessment, Disease Monitoring editorial team (companion journal to Alzheimer's & Dementia) convened an interdisciplinary discussion in 2019 to identify a path to expedite the development of retinal biomarkers capable of identifying biological changes associated with AD, and for tracking progression of disease severity over time. As different retinal imaging modalities provide different types of structural and/or functional information, the discussion reflected on these modalities and their respective strengths and weaknesses. Discussion further focused on the importance of defining the context of use to help guide the development of retinal biomarkers. Moving from research to context of use, and ultimately to clinical evaluation, this article outlines ongoing retinal imaging research today in Alzheimer's and other brain diseases, including a discussion of future directions for this area of study.
Original languageEnglish
JournalAlzheimer's and Dementia
DOIs
Publication statusE-pub ahead of print - 2020

Cite this